Androgen receptor inhibitor

This page covers all Androgen receptor inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Androgen receptor, Glucocorticoid receptor, Prostate-specific antigen, Androgen receptor, Androgen receptor (AR).

Targets

Androgen receptor, Glucocorticoid receptor, Prostate-specific antigen · Androgen receptor · Androgen receptor (AR)

Marketed (2)

• MDV3100 · Pfizer Inc. · Oncology
• Xtandi · Astellas Pharma · Oncology
  Enzalutamide competitively inhibits androgen binding to androgen receptors, blocking nuclear translocation and DNA interaction.

Phase 3 pipeline (1)

• TH07 · Triple Hair Inc · Oncology
  TH07 is a small molecule that targets the androgen receptor.

Phase 2 pipeline (3)

• ARSI · City of Hope Medical Center · Oncology
  ARSI is an androgen receptor signaling inhibitor that blocks androgen receptor activity to suppress hormone-dependent cancer cell growth.
• ARN-509 · Aragon Pharmaceuticals, Inc. · Oncology
  ARN-509 is an androgen receptor inhibitor.
• ADT for 9 months and ARTA for 6 months · Tata Memorial Centre · Oncology
  Androgen deprivation therapy (ADT) involves blocking the production of androgens, such as testosterone, which fuel the growth of prostate cancer cells. Androgen receptor signaling inhibitor (ARTA) works by blocking the androgen receptor, preventing cancer cells from receiving the signals they need to grow and multiply.

Phase 1 pipeline (2)

• ARV-110 in Combination with Abiraterone · Arvinas Androgen Receptor, Inc. · Oncology
  Androgen receptor inhibitor
• AZD8835 in combination with fulvestrant · AstraZeneca · Oncology
  AZD8835 is a selective and potent inhibitor of the androgen receptor.